» Articles » PMID: 22674985

Antibody-dependent Cellular Cytotoxicity Against Primary HIV-infected CD4+ T Cells is Directly Associated with the Magnitude of Surface IgG Binding

Abstract

Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is thought to potentially play a role in vaccine-induced protection from HIV-1. The characteristics of such antibodies remain incompletely understood. Furthermore, correlates between ADCC and HIV-1 immune status are not clearly defined. We screened the sera of 20 HIV-1-positive (HIV-1(+)) patients for ADCC. Normal human peripheral blood mononuclear cells were used to derive HIV-infected CD4(+) T cell targets and autologous, freshly isolated, natural killer (NK) cells in a novel assay that measures granzyme B (GrB) and HIV-1-infected CD4(+) T cell elimination (ICE) by flow cytometry. We observed that complex sera mediated greater levels of ADCC than anti-HIV-1 envelope glycoprotein (Env)-specific monoclonal antibodies and serum-mediated ADCC correlated with the amount of IgG and IgG1 bound to HIV-1-infected CD4(+) T cells. No correlation between ADCC and viral load, CD4(+) T cell count, or neutralization of HIV-1(SF162) or other primary viral isolates was detected. Sera pooled from clade B HIV-1(+) individuals exhibited breadth in killing targets infected with HIV-1 from clades A/E, B, and C. Taken together, these data suggest that the total amount of IgG bound to an HIV-1-infected cell is an important determinant of ADCC and that polyvalent antigen-specific Abs are required for a robust ADCC response. In addition, Abs elicited by a vaccine formulated with immunogens from a single clade may generate a protective ADCC response in vivo against a variety of HIV-1 species. Increased understanding of the parameters that dictate ADCC against HIV-1-infected cells will inform efforts to stimulate ADCC activity and improve its potency in vaccinees.

Citing Articles

Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.

Grunst M, Ladd R, Clark N, Gil H, Klenchin V, Mason R PLoS Pathog. 2023; 19(5):e1011407.

PMID: 37253062 PMC: 10256149. DOI: 10.1371/journal.ppat.1011407.


Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.

Kuriakose Gift S, Wieczorek L, Sanders-Buell E, Zemil M, Molnar S, Donofrio G J Virol. 2023; 97(2):e0163522.

PMID: 36749076 PMC: 9973046. DOI: 10.1128/jvi.01635-22.


Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.

Molinos-Albert L, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J Nat Commun. 2022; 13(1):1944.

PMID: 35410989 PMC: 9001681. DOI: 10.1038/s41467-022-29511-1.


Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission.

Thomas A, Coote C, Moreau Y, Isaac J, Ewing A, Kourtis A JCI Insight. 2022; 7(9).

PMID: 35324477 PMC: 9090239. DOI: 10.1172/jci.insight.159435.


Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.

Wang S, Yates N, Pollara J, Voronin Y, Stanfield-Oakley S, Han D NPJ Vaccines. 2022; 7(1):18.

PMID: 35140230 PMC: 8828892. DOI: 10.1038/s41541-022-00441-9.


References
1.
Hezareh M, Hessell A, Jensen R, van de Winkel J, Parren P . Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001; 75(24):12161-8. PMC: 116112. DOI: 10.1128/JVI.75.24.12161-12168.2001. View

2.
Migueles S, Osborne C, Royce C, Compton A, Joshi R, Weeks K . Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29(6):1009-21. PMC: 2622434. DOI: 10.1016/j.immuni.2008.10.010. View

3.
Stratov I, Chung A, Kent S . Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol. 2008; 82(11):5450-9. PMC: 2395196. DOI: 10.1128/JVI.01952-07. View

4.
Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

5.
Dalgleish A, Sinclair A, Steel M, Beatson D, Ludlam C, Habeshaw J . Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol. 1990; 81(1):5-10. PMC: 1535031. DOI: 10.1111/j.1365-2249.1990.tb05283.x. View